0001209191-22-026892.txt : 20220503 0001209191-22-026892.hdr.sgml : 20220503 20220503190541 ACCESSION NUMBER: 0001209191-22-026892 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220430 FILED AS OF DATE: 20220503 DATE AS OF CHANGE: 20220503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hansen Gwenn CENTRAL INDEX KEY: 0001817160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 22889052 MAIL ADDRESS: STREET 1: C/O NURIX THERAPEUTICS, INC. STREET 2: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-30 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817160 Hansen Gwenn C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Scientific Officer Common Stock 2022-04-30 4 M 0 3206 0.00 A 18249 D Common Stock 2022-05-02 4 S 0 1098 11.75 D 17151 D Restricted Stock Units 0.00 2022-04-30 4 M 0 3206 0.00 D Common Stock 3206 48102 D Includes 846 shares of Common Stock acquired by the Reporting Person on February 15, 2022 pursuant to the Issuer's employee stock purchase plan. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. /s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen 2022-05-03